Cancer drug trial pulled before it even started
NCT ID NCT05845307
First seen Nov 16, 2025 · Last updated May 14, 2026 · Updated 19 times
Summary
This trial aimed to see if the drug TTI-101 could shrink HPV-negative head and neck cancers when given just before planned surgery. It was designed for people with stage II to IV cancer that could be removed. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.